The Clinical and Experimental Therapeutics (CET) Program is a cohesive, integrated group of 51 members representing nine different Departments. The overall goal of the Program is to foster interaction between basic and clinical investigators to develop innovative therapies for cancer patients. As the major clinical and translational arm of the UCCCC, the Program interfaces with all of the other Programs to seamlessly integrate fundamental cancer research with clinical care and clinical research objectives. The two co-leaders, M. Eileen Dolan, PhD, a laboratory-based scientist with experience in preclinical and translational studies, and Walter Stadler, MD, a medical oncologist with expertise in clinical trials and clinical drug development, have complementary expertise, and work well together to promote the goals of the CET Program. They jointly address Program-specific issues, including membership, funding, and scientific direction. Dr. Dolan is co-PI of a T32 Clinical Therapeutics training grant and Dr. Stadler is co-PI of an oncology Paul Calabresi K12 grant; therefore, they are also well integrated into the training and mentorship of fellows and junior faculty. Program members place an emphasis on translational and clinical research, as well as lead studies conducted by national cooperative groups to facilitate the development of new therapies for hematologic malignancies and solid tumors. The Program has a long-standing interest in all phases of clinical drug development from preclinical to early-phase trials to cooperative group led Phase III trials with a strong focus on pharmacogenomics and pharmacology. The specific scientific aims of the CET Program are to: 1) Pursue a broad Program of pharmacogenomic, molecular target, and biomarker research in the preclinical and clinical settings as well as to translate the findings into clinical practice; 2) Foster interactions between basic and clinical investigators that will result in innovative and effective therapies; 3) Integrate new drugs and immunotherapeutics into the development of multimodality therapies for patients with hematologic malignancies and advanced solid tumors; and 4) Train the next generation of leaders in clinical and translational research through formal mentoring and career development efforts. These scientific goals are achieved through programmatic efforts emphasizing three themes: pharmacogenomics, molecular targets, and biomarkers through preclinical and clinical studies. Program members are supported by $21,333,004 in total funding (DC), with $7,712,492 in peer-reviewed funding ($5,380,171 from NCI), and $13,620,512 in non-peer- reviewed support. For the 2013-2016 period, Program members have 888 peer-reviewed publications, with 20% interprogrammatic, 28% intraprogrammatic, and 9% both intra- and interprogrammatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-45
Application #
9904516
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Liu, Hongtao; Zha, Yuanyuan; Choudhury, Noura et al. (2018) WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia. Exp Hematol Oncol 7:1
Nageeb, Shaheen; Vu, Milkie; Malik, Sana et al. (2018) Adapting a religious health fatalism measure for use in Muslim populations. PLoS One 13:e0206898
Ferreira, Caroline M; Williams, Jesse W; Tong, Jiankun et al. (2018) Allergen Exposure in Lymphopenic Fas-Deficient Mice Results in Persistent Eosinophilia Due to Defects in Resolution of Inflammation. Front Immunol 9:2395
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188

Showing the most recent 10 out of 668 publications